Back HIV/AIDS HIV/AIDS Topics HIV Prevention

CROI 2015: Combining PrEP and ART Could Nearly Eliminate HIV Infection

Giving both pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) to heterosexual couples where one partner has HIV (serodiscordant couples) can almost eliminate the chance of infection of the HIV negative partner, a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle has shown.

alt

Read more:

CROI 2015: Maraviroc Levels in Vaginal and Rectal Tissues May Not Be High Enough for PrEP

Levels of the HIV entry inhibitor maraviroc (Selzentry) in vaginal and rectal tissues did not reach high enough levels with a single oral dose to confer protection against HIV in a laboratory study, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Multiple doses, however, could still potentially be effective for pre-exposure prophylaxis, or PrEP.

alt

Read more:

CROI 2015: Tenofovir Vaginal Gel Not Effective Overall Against HIV [VIDEO]

The FACTS 001 trial evaluating a vaginal microbicide gel containing tenofovir did not show overall effectiveness for preventing HIV infection among young women in South Africa, although the product did appear to provide some protection for women who were able to use it consistently, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

Read more:

CROI 2015: Disappointing Result for Tenofovir Gel Microbicide

Among some highly promising results from HIV prevention studies presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle, there was one disappointment. FACTS 001, a study testing the efficacy against HIV of a vaginal microbicide gel containing tenofovir, produced a null result: there was no difference in the HIV infection rate for young women given the active gel and the rate for those given a placebo gel.

alt

Read more:

Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.

Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.

HIVandHepatitis.com coverage by topic

CROI website

3/2/15

alt